These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

505 related items for PubMed ID: 25253414

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacological management of acromegaly: a current perspective.
    Manjila S, Wu OC, Khan FR, Khan MM, Arafah BM, Selman WR.
    Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
    [Abstract] [Full Text] [Related]

  • 3. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
    Ferone D, Pivonello R, Lastoria S, Faggiano A, Del Basso de Caro ML, Cappabianca P, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
    [Abstract] [Full Text] [Related]

  • 4. [Novel pharmacologic therapies in acromegaly].
    Góth M, Hubina E, Kovács L, Szabolcs I.
    Orv Hetil; 2002 May 12; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [Abstract] [Full Text] [Related]

  • 5. Long-term treatment with bromocriptine of a plurihormonal pituitary adenoma secreting thyrotropin, growth hormone and prolactin.
    Shimatsu A, Murabe H, Nakamura Y, Mizuta H, Ihara C, Nakao K.
    Endocr J; 1999 Feb 12; 46(1):159-65. PubMed ID: 10426581
    [Abstract] [Full Text] [Related]

  • 6. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex.
    van der Lely AJ, Harris AG, Lamberts SW.
    Clin Endocrinol (Oxf); 1992 Aug 12; 37(2):181-5. PubMed ID: 1395069
    [Abstract] [Full Text] [Related]

  • 7. Acromegaly with normal growth hormone levels: response to Sandostatin-LAR treatment.
    Shimon I, Nass D, Hadani M.
    Pituitary; 2000 May 12; 2(4):289-94. PubMed ID: 11081151
    [Abstract] [Full Text] [Related]

  • 8. [Estimation of efficacy of the octreotide LAR administration in the patients with somatotropinoma].
    Waśko R, Bolko P, Kostrzewski J, Horst-Sikorska W, Liebert W, Sowiński J.
    Pol Arch Med Wewn; 2001 Aug 12; 106(2):693-8. PubMed ID: 11926144
    [Abstract] [Full Text] [Related]

  • 9. Desensitization to somatostatin analogue (Octreotide) observed in a patient with acromegaly.
    Haraguchi K, Ohtaka M, Takazawa K, Endo T, Onaya T.
    Endocr J; 1995 Apr 12; 42(2):295-300. PubMed ID: 7627275
    [Abstract] [Full Text] [Related]

  • 10. Cabergoline in the treatment of acromegaly: a study in 64 patients.
    Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A.
    J Clin Endocrinol Metab; 1998 Feb 12; 83(2):374-8. PubMed ID: 9467544
    [Abstract] [Full Text] [Related]

  • 11. Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors.
    Freda PU, Reyes CM, Nuruzzaman AT, Sundeen RE, Khandji AG, Post KD.
    Pituitary; 2004 Feb 12; 7(1):21-30. PubMed ID: 15638294
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of different dopaminergic agents in the treatment of acromegaly.
    Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F, Cirillo S, Merola B, Lombardi G.
    J Clin Endocrinol Metab; 1997 Feb 12; 82(2):518-23. PubMed ID: 9024247
    [Abstract] [Full Text] [Related]

  • 14. Medical therapy for acromegaly.
    Newman CB.
    Endocrinol Metab Clin North Am; 1999 Mar 12; 28(1):171-90. PubMed ID: 10207690
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The efficacy of medical treatment in patients with acromegaly in clinical practice.
    Lee SY, Kim JH, Lee JH, Kim YH, Cha HJ, Kim SW, Paek SH, Shin CS.
    Endocr J; 2018 Jan 30; 65(1):33-41. PubMed ID: 28931779
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Acromegaly with normal IGF-1 levels probably due to poorly controlled diabetes mellitus.
    Arihara Z, Sakurai K, Yamada S, Murakami O, Takahashi K.
    Tohoku J Exp Med; 2008 Dec 30; 216(4):325-9. PubMed ID: 19060447
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.
    Cozzi R, Attanasio R, Lodrini S, Lasio G.
    Clin Endocrinol (Oxf); 2004 Aug 30; 61(2):209-15. PubMed ID: 15272916
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.